Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242134 | 0.81 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL57641 | 0.78 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL28053412 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL27938619 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL27720358 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL27266457 | 0.74 | ALDH1A1 (0.38) | KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL18705611 | 0.71 | HTR7 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL455316 | 0.70 | — | — | |
| SCHEMBL8656230 | 0.70 | KDM4E (0.31) | KDM4E | |
| SCHEMBL29160711 | 0.70 | SMN1; SMN2 (0.35) | KDM4EALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850329-A | Cycloterpyriaryl phosphines, their preparation and use | 东莞市均成高新材料有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-110240616-B | Tribiaryl monophosphine ligands, methods for their preparation and use in catalytic coupling reactions | 东莞市均成高新材料有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-115385956-A | Biaryl diphosphine ligands and transition metal complexes thereof | 东莞市均成高新材料有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-110240616-B | Tribiaryl monophosphine ligands, methods for their preparation and use in catalytic coupling reactions | 东莞市均成高新材料有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 3277/4885ALDH1A1 1776/4885MAPK1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.